Akero Therapeutics (AKRO) News Today $44.92 +0.05 (+0.11%) Closing price 04:00 PM EasternExtended Trading$46.00 +1.08 (+2.40%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Alkeon Capital Management LLC Sells 1,563,736 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Alkeon Capital Management LLC reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 47.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,761,268 shares of tMay 5 at 7:44 AM | marketbeat.com165,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by 5AM Venture Management LLC5AM Venture Management LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 165,000 shares of the company's stock, valued at approximately $4,5May 4 at 7:15 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC lessened its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 5.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,295 shares of the coMay 4 at 5:06 AM | marketbeat.comAquatic Capital Management LLC Buys 14,841 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Aquatic Capital Management LLC lifted its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 463.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,041 shares of the company's stock after purchasing an additional 14,841 shaMay 4 at 4:37 AM | marketbeat.comAkero Therapeutics (AKRO) Projected to Post Quarterly Earnings on FridayAkero Therapeutics (NASDAQ:AKRO) will be releasing its Q1 2025 earnings before the market opens on Friday, May 9. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-9-akero-therapeutics-inc-stock/)May 4 at 1:05 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Consensus Rating of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has been assigned an average rating of "Buy" from the nine brokerages that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brMay 2 at 4:39 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Tower Research Capital LLC TRCTower Research Capital LLC TRC lifted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 770.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,188 shMay 2 at 4:15 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Has $9.80 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Emerald Mutual Fund Advisers Trust reduced its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 352,180 shares of the company's stock after selling 63,021 shares during the pMay 1, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Timothy Rolph Sells 6,250 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 6,250 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $41.03, for a total value of $256,437.50. Following the completion of the transaction, the insider now directly owns 169,721 shares in the company, valued at $6,963,652.63. This represents a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.April 30, 2025 | marketbeat.comForesite Capital Management VI LLC Acquires New Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Foresite Capital Management VI LLC acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 365,000 sharesApril 30, 2025 | marketbeat.comAkero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025April 30, 2025 | globenewswire.comT. Rowe Price Investment Management Inc. Sells 630,048 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)T. Rowe Price Investment Management Inc. trimmed its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 48.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 670,048 shares of the company's stock after selling 630,048 shares duringApril 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Increases Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Price T Rowe Associates Inc. MD raised its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 13.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 4,321,972 shares of the company's stock after acquiring an additional 513,613 shares during the pApril 30, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Position Increased by Invesco Ltd.Invesco Ltd. lifted its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 27.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 98,463 shares of the company's stock after acquiring an additional 21,086 shares during the period. InApril 30, 2025 | marketbeat.comDark Forest Capital Management LP Takes $470,000 Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Dark Forest Capital Management LP bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,893 shares of the company's stock, valued at approximateApril 29, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Wells Fargo & Company MNWells Fargo & Company MN raised its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 14.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,867 shares of the company'sApril 28, 2025 | marketbeat.comJump Financial LLC Lowers Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Jump Financial LLC lessened its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 71.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,854 shares of the company's stock after sellApril 27, 2025 | marketbeat.comMarshall Wace LLP Purchases Shares of 275,074 Akero Therapeutics, Inc. (NASDAQ:AKRO)Marshall Wace LLP acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 275,074 shares of the company's stock, valued at approximately $7,653,000. MaApril 25, 2025 | marketbeat.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. ...April 23, 2025 | gurufocus.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmApril 23, 2025 | globenewswire.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Rock Springs Capital Management LPRock Springs Capital Management LP raised its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 946,499 shares of the company's stock after purchasing an additiApril 23, 2025 | marketbeat.comB Group Inc. Makes New $7.23 Million Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)B Group Inc. acquired a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 260,000 shares of the company's stockApril 23, 2025 | marketbeat.comWalleye Capital LLC Acquires Shares of 134,705 Akero Therapeutics, Inc. (NASDAQ:AKRO)Walleye Capital LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 134,705 shares of the company's stock, valued at approximately $3,747,0April 20, 2025 | marketbeat.comCatriona Yale Sells 9,073 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 9,073 shares of the stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $37.91, for a total value of $343,957.43. Following the completion of the sale, the insider now owns 95,034 shares of the company's stock, valued at $3,602,738.94. This trade represents a 8.72 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.April 18, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 9,073 SharesApril 17, 2025 | insidertrades.comGeode Capital Management LLC Reduces Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Geode Capital Management LLC decreased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 0.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,559,631 shares of the company's stock after selling 11,381 sharesApril 16, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) is University of Wisconsin Foundation's 6th Largest PositionUniversity of Wisconsin Foundation decreased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,630 shares ofApril 15, 2025 | marketbeat.comOptimize Financial Inc Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Optimize Financial Inc purchased a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,336 shares of the companyApril 15, 2025 | marketbeat.comF M Investments LLC Invests $1.27 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)F M Investments LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 45,778 shares of the company's stock, valued at apprApril 14, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)JPMorgan Chase & Co. raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 528,207 shares of the company's stock after acqApril 14, 2025 | marketbeat.comSei Investments Co. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)Sei Investments Co. bought a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,887 shares of the company's stock, valued at approximately $30April 13, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 SharesApril 12, 2025 | insidertrades.comExodusPoint Capital Management LP Grows Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)ExodusPoint Capital Management LP raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,207 shares of the company's stock after buyApril 12, 2025 | marketbeat.comVanguard Group Inc. Has $103.06 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Vanguard Group Inc. grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,704,411 shares of the company's stock after acquiring an addiApril 12, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 6,250 Shares of StockApril 11, 2025 | insidertrades.comSchroder Investment Management Group Reduces Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Schroder Investment Management Group decreased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 86.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,615 shares of the cApril 9, 2025 | marketbeat.com151,200 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Springhill Fund Asset Management HK Co LtdSpringhill Fund Asset Management HK Co Ltd purchased a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 151,200 shares of the company's sApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)KLP Kapitalforvaltning AS purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,000 shares of the company's stock, valued at approximatelyApril 8, 2025 | marketbeat.comAmerican Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)American Century Companies Inc. grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 55.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,442 shares of the compaApril 8, 2025 | marketbeat.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmApril 7, 2025 | investing.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received an average recommendation of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1 year target price among analysts thatApril 7, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Alliancebernstein L.P. lessened its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,839,281 shares of the company's stock after selling 177,807 shares durApril 7, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Trading 7.3% Higher - Here's WhyAkero Therapeutics (NASDAQ:AKRO) Shares Up 7.3% - Here's WhyApril 4, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Position Trimmed by Wellington Management Group LLPWellington Management Group LLP trimmed its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,376,961 shares of the company's stoApril 4, 2025 | marketbeat.comAkero Therapeutics Enters Oversold Territory (AKRO)April 3, 2025 | nasdaq.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comNEOS Investment Management LLC Has $894,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)NEOS Investment Management LLC lowered its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,150 shares of theApril 1, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Insider Buying ActivityAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up on Insider Buying ActivityMarch 29, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Director Acquires $2,177,500.00 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham purchased 50,000 shares of the company's stock in a transaction dated Thursday, March 27th. The shares were bought at an average cost of $43.55 per share, for a total transaction of $2,177,500.00. Following the acquisition, the director now owns 1,200,000 shares in the company, valued at approximately $52,260,000. The trade was a 4.35 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 28, 2025 | marketbeat.comG. Walmsley Graham Purchases 91,309 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham acquired 91,309 shares of Akero Therapeutics stock in a transaction dated Tuesday, March 25th. The shares were bought at an average cost of $44.75 per share, with a total value of $4,086,077.75. Following the transaction, the director now owns 1,091,309 shares in the company, valued at approximately $48,836,077.75. This trade represents a 9.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 28, 2025 | marketbeat.com Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼1.140.72▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼168▲AKRO Articles Average Week Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Roivant Sciences News Revolution Medicines News Lantheus News BridgeBio Pharma News TG Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts